Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18981230

Ranibizumab (Lucentis) versus bevacizumab (Avastin) : modelling cost effectiveness

Author
RAFTERY, James1 ; CLEGG, Andrew1 ; JONES, Jeremy1 ; SENG CHUEN TAN1 ; LOTERY, Andrew2
[1] Wessex Institute for Health R&D, Medical School, University of Southampton, Southampton, United Kingdom
[2] University of Southampton, Southampton Eye Unit, Southampton General Hospital, Southampton, United Kingdom
Source

British journal of ophthalmology. 2007, Vol 91, Num 9, pp 1244-1246, 3 p ; ref : 19 ref

CODEN
BJOPAL
ISSN
0007-1161
Scientific domain
Ophthalmology
Publisher
BMJ, London
Publication country
United Kingdom
Document type
Article
Language
English
Keyword (fr)
Analyse coût efficacité Economie santé Etude comparative Immunomodulateur Modélisation Ophtalmologie Anti-VEGF Ranibizumab
Keyword (en)
Cost efficiency analysis Health economy Comparative study Immunomodulator Modeling Ophthalmology Ranibizumab
Keyword (es)
Análisis costo eficacia Economía salud Estudio comparativo Inmunomodulador Modelización Oftalmología Ranibizumab
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B09 Ophthalmology / 002B09N Miscellaneous

Discipline
Ophthalmology
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
18981230

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web